Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press166410.17650/1726-9776-2023-19-2-17-28DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак почкиCorrelation between 3D morphometric characteristics of kidney tumors and their histological structureКорреляция 3D-морфотопометрических характеристик опухоли почки с ее гистологическим строениемhttps://orcid.org/0000-0002-0401-8780FievD. N.ФиевД. Н.
Russian Federation

Dmitriy Nikolaevich Fiev

Build. 1, 2 Bol’shaya Pirogovskaya St., Moscow 119435, Russia 

Дмитрий Николаевич Фиев 

Россия, 119435 Москва, ул. Большая Пироговская, 2, стр. 1 

fiev@mail.ruhttps://orcid.org/0000-0001-6419-0155SirotaE. S.СиротаЕ. С.
Russian Federation

Build. 1, 2 Bol’shaya Pirogovskaya St., Moscow 119435, Russia

Россия, 119435 Москва, ул. Большая Пироговская, 2, стр. 1 

essirota@mail.ruhttps://orcid.org/0000-0002-2389-3820KozlovV. V.КозловВ. В.
Russian Federation

N.A. Semashko Department of Public Health and Healthcare

Build. 1, 2 Bol’shaya Pirogovskaya St., Moscow 119435, Russia

кафедра общественного здоровья и здравоохранения им. Н.А. Семашко

Россия, 119435 Москва, ул. Большая Пироговская, 2, стр. 1

kvv.doc@gmail.comhttps://orcid.org/0000-0003-0441-4799ProskuraA. V.ПроскураА. В.
Russian Federation

Build. 1, 2 Bol’shaya Pirogovskaya St., Moscow 119435, Russia 

Россия, 119435 Москва, ул. Большая Пироговская, 2, стр. 1 

proskura777@yandex.ruhttps://orcid.org/0000-0003-1121-9430ShpotE. V.ШпотьЕ. В.

Build. 1, 2 Bol’shaya Pirogovskaya St., Moscow 119435, Russia 

Россия, 119435 Москва, ул. Большая Пироговская, 2, стр. 1 

shpot_e_v@staff.sechenov.ruhttps://orcid.org/0000-0002-4001-5317ChernenkiyM. M.ЧерненькийМ. М.
Russian Federation

Build. 1, 2 Bol’shaya Pirogovskaya St., Moscow 119435, Russia 

Инженер-физик

Россия, 119435 Москва, ул. Большая Пироговская, 2, стр. 1 

chernenkiy_m_m@staff.sechenov.ruhttps://orcid.org/0000-0001-5968-9883ChernenkiyI. M.ЧерненькийИ. М.
Russian Federation

Build. 1, 2 Bol’shaya Pirogovskaya St., Moscow 119435, Russia 

Инженер-программист

Россия, 119435 Москва, ул. Большая Пироговская, 2, стр. 1 

chernenkiy_i_m@staff.sechenov.ruhttps://orcid.org/0000-0001-9017-8205PuzakovK. B.ПузаковК. Б.
Russian Federation

Build. 1, 24 Petrovka St., Moscow 127051, Russia

Россия, 127051 Москва, ул. Петровка, 24, стр. 1 

mrictdoc@mail.ruhttps://orcid.org/0000-0002-7096-7423Azil’gareevaK. R.АзильгарееваК. Р.
Russian Federation

Build. 1, 2 Bol’shaya Pirogovskaya St., Moscow 119435, Russia 

Россия, 119435 Москва, ул. Большая Пироговская, 2, стр. 1 

camilla.azilgareeva@yandex.ruhttps://orcid.org/0000-0003-0548-190XIsmailovKh. M.ИсмаиловХ. М.
Russian Federation

Build. 1, 2 Bol’shaya Pirogovskaya St., Moscow 119435, Russia 

Россия, 119435 Москва, ул. Большая Пироговская, 2, стр. 1 

halilismailov2013@mail.ruhttps://orcid.org/0000-0003-2173-0566ButnaruD. V.БутнаруД. В.
Russian Federation

Build. 1, 2 Bol’shaya Pirogovskaya St., Moscow 119435, Russia 

Россия, 119435 Москва, ул. Большая Пироговская, 2, стр. 1 

butnaru_d_v@staff.sechenov.ruhttps://orcid.org/0000-0003-1525-6247KutikovA.КутиковА.
United States

333 Cottman Avenue, Philadelphia, PA 19111 USA 

США, 19111 Пенсильвания, Филадельфия, Коттман-авеню, 333 

alexander.kutikov@fccc.eduhttps://orcid.org/0000-0001-9510-9487VinarovA. Z.ВинаровА. З.
Russian Federation

Build. 1, 2 Bol’shaya Pirogovskaya St., Moscow 119435, Russia 

Россия, 119435 Москва, ул. Большая Пироговская, 2, стр. 1 

avinarov@mail.ruInstitute of Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)Институт урологии и репродуктивного здоровья человека ФГАОУ ВО Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России (Сеченовский Университет)I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)ФГАОУ ВО Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России (Сеченовский Университет)Scientific and Practical Clinical Center for Diagnostics and Telemedicine Technologies, Moscow Healthcare DepartmentГБУЗ г. Москвы «Научно-практический клинический центр диагностики и телемедицинских технологий Департамента здравоохранения г. Москвы»Fox Chase Cancer CenterОнкологический центр Фокс Чейз1408202319217281802202330052023https://oncourology.abvpress.ru/oncur/article/view/1664

Aim. To assess the correlation between clinical characteristics (sex, age, and maximum tumor size), 3D morphometric characteristics of renal lesions obtained through processing of multispiral computed tomography data, and renal tumor histology.

Materials and methods. Evaluation of kidney tumor malignancy on the basis of comparative analysis of primarily morphometric characteristics of the lesion obtained through processing of multispiral computed tomography data and histological tumor structure is presented. Data of 308 patients (175 (56.8 %) males and 133 (43.2 %) females) with unilateral renal tumors were analyzed.

Results. Multivariable analysis showed that malignancy of kidney tumor is associated with sex (male), location in the middle segment, tumor size, tumor shape (spherical with conical base) (24.8 %), while mushroom-like lesion shape was more common in benign tumors (35.2 %). In univariate models, only two variables were statistically significant predictors: patient sex and tumor shape.

Conclusion. The developed logistic model based on analysis of such predictors as sex and kidney tumor shape has a high percentage (87.6 %) of correct predictions of tumor histological structure.

Цель исследования – оценить корреляцию общих показателей (пол, возраст, максимальный размер опухоли), 3D-морфотопометрических характеристик опухолевого узла почки, полученных при постпроцессинговой обработке данных мультиспиральной компьютерной томографии, с характером гистологического строения новообразования.Материалы и методы. Представлен опыт оценки злокачественности опухоли почки на основании сравнительного анализа преимущественно морфотопометрических характеристик новообразования почки, полученных при постпроцессинговой обработке данных мультиспиральной компьютерной томографии, и гистологического строения опухоли. Проанализированы данные 308 пациентов (175 (56,8 %) мужчин и 133 (43,2 %) женщины) с односторонней опухолью почки.Результаты. Многофакторный анализ показал, что злокачественность новообразования почки ассоциирована с полом (мужским), локализацией в среднем сегменте почки, размером опухоли, формой (шаровидной с конусовидным основанием) (24,8 %), в то время как грибовидная форма опухолевого узла наиболее часто наблюдалась при доброкачественных новообразованиях (35,2 %). В однофакторных моделях в качестве статистически значимых предикторов показали себя только 2 фактора – пол пациента и форма опухоли.Заключение. Полученная логистическая модель, основанная на анализе таких предикторов, как пол и форма новообразования почки, имеет высокий процент (87,6 %) корректных предсказаний его гистологического строения.

multispiral computed tomography3D modelingtumor shapemalignancy predictionactive observationrenal biopsyrenal lesion without internal fat componentмультиспиральная компьютерная томография3D-моделированиеформа опухоли, прогнозирование злокачественностиактивное наблюдениебиопсия почкиобразование почкиобедненное жировым компонентомHindman N., Ngo L., Genega E.M. et al. Angiomyolipoma with minimal fat: Can it be differentiated from clear cell renal cell carcinoma by using standard MR techniques? Radiology 2012;265(2):468–77. DOI: 10.1148/radiol.12112087Campbell S., Uzzo R.G., Allaf M.E. et al. Renal mass and localized renal cancer: AUA guideline. J Urol 2017;198(3):520–9. DOI: 10.1016/j.juro.2017.04.100Wang H.K., Zhu Y., Yao X.D. et al. External validation of a nomogram using RENAL nephrometry score to predict high grade renal cell carcinoma. J Urol 2012;187(5):1555–60. DOI: 10.1016/j.juro.2011.12.099Richard P.O., Jewett M.A.S., Bhatt J.R. et al. Renal Tumor biopsy for small renal masses: a single-center 13-year experience. Eur Urol 2015;68(6):1007–13. DOI: 10.1016/j.eururo.2015.04.004Marconi L., Dabestani S., Lam T.B. et al. Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol 2016;69(4):660–73. DOI: 10.1016/j.eururo.2015.07.072Shannon B.A., Cohen R.J., de Bruto H. et al. The value of preoperative needle core biopsy for diagnosing benign lesions amongShannon B.A., Cohen R.J., de Bruto H. et al. The value of preoperative needle core biopsy for diagnosing benign lesions among small, incidentally detected renal masses. J Urol 2008;180:1257–61. DOI: 10.1016/j.juro.2008.06.030small, incidentally detected renal masses. J Urol 2008;180:1257–61. DOI: 10.1016/j.juro.2008.06.030Veltri A., Garetto I., Tosetti I. et al. Diagnostic accuracy and clinical impact of imaging-guided needle biopsy of renal masses. Retrospective analysis on 150 cases. Eur Radiol 2011;21(2):393–401. DOI: 10.1007/s00330-010-1938-9Veltri A., Garetto I., Tosetti I. et al. Diagnostic accuracy and clinical impact of imaging-guided needle biopsy of renal masses. Retrospective analysis on 150 cases. Eur Radiol 2011;21(2):393–401. DOI: 10.1007/s00330-010-1938-9Abel E.J., Culp S.H., Matin S.F. et al. Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: Comparison with nephrectomy assessment. J Urol 2010;184(5):1877–81. DOI: 10.1016/j.juro.2010.06.105Abel E.J., Culp S.H., Matin S.F. et al. Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: Comparison with nephrectomy assessment. J Urol 2010;184(5):1877–81. DOI: 10.1016/j.juro.2010.06.105Leveridge M.J., Finelli A., Kachura J.R. et al. Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. Eur Urol 2011;60(3):578–84. DOI: 10.1016/j.eururo.2011.06.021Leveridge M.J., Finelli A., Kachura J.R. et al. Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. Eur Urol 2011;60(3):578–84. DOI: 10.1016/j.eururo.2011.06.021Breda A., Treat E.G., Haft-Candell L. et al. Comparison of accuracy of 14-, 18- and 20-G needles in ex-vivo renal mass biopsy: a prospective, blinded study. BJU Int 2010;105(7):940–5. DOI: 10.1111/j.1464-410X.2009.08989.xBreda A., Treat E.G., Haft-Candell L. et al. Comparison of accuracy of 14-, 18- and 20-G needles in ex-vivo renal mass biopsy: a prospective, blinded study. BJU Int 2010;105(7):940–5. DOI: 10.1111/j.1464-410X.2009.08989.xMotzer R.J., Barrios C.H., Kim T.M. et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 2014;32(25):2765–72. DOI: 10.1200/JCO.2013.54.6911Motzer R.J., Barrios C.H., Kim T.M. et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 2014;32(25):2765–72. DOI: 10.1200/JCO.2013.54.6911Patel H.D., Johnson M.H., Pierorazio P.M. et al. Diagnostic accuracy and risks of biopsy in the diagnosis of a renal mass suspicious for localized renal cell carcinoma: systematic review of the literature. J Urol 2016;195(5):1340–7. DOI: 10.1016/j.juro.2015.11.029Patel H.D., Johnson M.H., Pierorazio P.M. et al. Diagnostic accuracy and risks of biopsy in the diagnosis of a renal mass suspicious for localized renal cell carcinoma: systematic review of the literature. J Urol 2016;195(5):1340–7. DOI: 10.1016/j.juro.2015.11.029Moch H., Amin M.B., Berney D.M. et al. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs – part A: renal, penile, and testicular tumours. Eur Urol 2022;82(5):458–68. DOI: 10.1016/j.eururo.2022.06.016Moch H., Amin M.B., Berney D.M. et al. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs – part A: renal, penile, and testicular tumours. Eur Urol 2022;82(5):458–68. DOI: 10.1016/j.eururo.2022.06.016Canvasser N.E., Kay F.U., Xi Y. et al. Diagnostic accuracy of multiparametric magnetic resonance imaging to identify clear cell renal cell carcinoma in cT1a renal masses. J Urol 2017;198(4):780–6. DOI: 10.1016/j.juro.2017.04.089Canvasser N.E., Kay F.U., Xi Y. et al. Diagnostic accuracy of multiparametric magnetic resonance imaging to identify clear cell renal cell carcinoma in cT1a renal masses. J Urol 2017;198(4):780–6. DOI: 10.1016/j.juro.2017.04.089AUA 2019: multiparametric magnetic resonance imaging identifies clear cell renal cell carcinoma with greater accuracy in higher stage lesions. Available at: https://www.urotoday.com/conference-highlights/aua-2019-annual-meeting/aua-2019-renal-cancer/112438-aua-2019-multiparametric-magnetic-resonance-imaging-identifies-clear-cell-renal-cell-carcinoma-with-greater-accuracy-inhigher-stage-lesions.html (accessed 26 May 2020).AUA 2019: multiparametric magnetic resonance imaging identifies clear cell renal cell carcinoma with greater accuracy in higher stage lesions. Available at: https://www.urotoday.com/conference-highlights/aua-2019-annual-meeting/aua-2019-renal-cancer/112438-aua-2019-multiparametric-magnetic-resonance-imaging-identifies-clear-cell-renal-cell-carcinoma-with-greater-accuracy-inhigher-stage-lesions.html (accessed 26 May 2020).Kim J.H., Sun H.Y., Hwang J. et al. Diagnostic accuracy of contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging of small renal masses in real practice: Sensitivity and specificity according to subjective radiologic interpretation. World J Surg Oncol 2016;14(1):260. DOI: 10.1186/s12957-016-1017-zKim J.H., Sun H.Y., Hwang J. et al. Diagnostic accuracy of contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging of small renal masses in real practice: Sensitivity and specificity according to subjective radiologic interpretation. World J Surg Oncol 2016;14(1):260. DOI: 10.1186/s12957-016-1017-zKay F.U., Canvasser N.E., Xi Y. et al. Diagnostic performance and interreader agreement of a standardized MR imaging approach in the prediction of small renal mass histology. Radiology 2018;287(2):543–53. DOI: 10.1148/radiol.2018171557Kay F.U., Canvasser N.E., Xi Y. et al. Diagnostic performance and interreader agreement of a standardized MR imaging approach in the prediction of small renal mass histology. Radiology 2018;287(2):543–53. DOI: 10.1148/radiol.2018171557Johnson B.A., Kim S., Steinberg R.L. et al. Diagnostic performance of prospectively assigned clear cell Likelihood scores (ccLS) in small renal masses at multiparametric magnetic resonance imaging. Urol Oncol 2019;37(12):941–6. DOI: 10.1016/j.urolonc.2019.07.023Johnson B.A., Kim S., Steinberg R.L. et al. Diagnostic performance of prospectively assigned clear cell Likelihood scores (ccLS) in small renal masses at multiparametric magnetic resonance imaging. Urol Oncol 2019;37(12):941–6. DOI: 10.1016/j.urolonc.2019.07.023Cornelis F., Tricaud E., Lasserre A.S. et al. Routinely performed multiparametric magnetic resonance imaging helps to differentiate common subtypes of renal tumours. Eur Radiol 2014;24(5):1068–80. DOI: 10.1007/s00330-014-3107-zCornelis F., Tricaud E., Lasserre A.S. et al. Routinely performed multiparametric magnetic resonance imaging helps to differentiate common subtypes of renal tumours. Eur Radiol 2014;24(5):1068–80. DOI: 10.1007/s00330-014-3107-zHötker A.M., Mazaheri Y., Wibmer A. et al. Differentiation of clear cell renal cell carcinoma from other renal cortical tumors by use of a quantitative multiparametric MRI approach. AJR Am J Roentgenol 2017;208(3):W85–91. DOI: 10.2214/AJR.16.16652Hötker A.M., Mazaheri Y., Wibmer A. et al. Differentiation of clear cell renal cell carcinoma from other renal cortical tumors by use of a quantitative multiparametric MRI approach. AJR Am J Roentgenol 2017;208(3):W85–91. DOI: 10.2214/AJR.16.16652Galmiche C., Bernhard J.C., Yacoub M. et al. Is multiparametric MRI useful for differentiating oncocytomas from chromophobe renal cell carcinomas? Am J Roentgenol 2017;208(2):343–50. DOI: 10.2214/AJR.16.16832Galmiche C., Bernhard J.C., Yacoub M. et al. Is multiparametric MRI useful for differentiating oncocytomas from chromophobe renal cell carcinomas? Am J Roentgenol 2017;208(2):343–50. DOI: 10.2214/AJR.16.16832Park J.J., Kim C.K. Small (<4 cm) renal tumors with predominantly low signal intensity on T2-weighted images: differentiation of minimal-fat angiomyolipoma from renal cell carcinoma. Am J Roentgenol 2017;208(1):124–30. DOI: 10.2214/AJR.16.16102Park J.J., Kim C.K. Small (<4 cm) renal tumors with predominantly low signal intensity on T2-weighted images: differentiation of minimal-fat angiomyolipoma from renal cell carcinoma. Am J Roentgenol 2017;208(1):124–30. DOI: 10.2214/AJR.16.16102Gao Y., Zhao H., Lu Y. et al. MicroRNAs as potential diagnostic biomarkers in renal cell carcinoma. Tumor Biol 2014;35(11):11041–50. DOI: 10.1007/s13277-014-2381-3Gao Y., Zhao H., Lu Y. et al. MicroRNAs as potential diagnostic biomarkers in renal cell carcinoma. Tumor Biol 2014;35(11):11041–50. DOI: 10.1007/s13277-014-2381-3Ellinger J., Alam J., Rothenburg J. et al. The long non-coding RNA lnc-ZNF180-2 is a prognostic biomarker in patients with clear cell renal cell carcinoma. Am J Cancer Res 2015;5(9):2799–807.Ellinger J., Alam J., Rothenburg J. et al. The long non-coding RNA lnc-ZNF180-2 is a prognostic biomarker in patients with clear cell renal cell carcinoma. Am J Cancer Res 2015;5(9):2799–807.Muselaers C.H.J., Boerman O.C., Oosterwijk E. et al. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol 2013;63(6):1101–6. DOI: 10.1016/j.eururo.2013.02.022Muselaers C.H.J., Boerman O.C., Oosterwijk E. et al. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol 2013;63(6):1101–6. DOI: 10.1016/j.eururo.2013.02.022